Cdex, Inc. (fka CDEX)

[capnmike]

Why I have high hopes for my CDEX investment.

In spite of the chaos surrounding this company and the history of it's intellectual property, I continue to hold my entire position (underwater, but never owned more, never had more dollars at risk).

Next week, for the first time in CDEX history, the company will be operated from the same location as the lab, and the company will have Tim Shriver as interim CEO. This means, for the very first time EVER, the CEO's name is on the issued patents and the patent applications. Rodney Boone did not have his name on a patent, and Rodney Boone did not seem to advance the technology to a point where it's potential was realized. Malcolm Philips did not have his name on a patent, and Malcolm Philips did not seem to advance the technology to a point where it's potential was realized. The promise was there, and then it was gone. The potential should have been realized. James O. Griffin did not have his name on a patent, and James O. Griffin did not seem to advance the technology to a point where it's potential was realized, and in fact, during his watch the company seemed close to failure.

The company still seems to have those that know what the technology can & should accomplish, and I've been lucky enough to see each of them interact with actual CDEX tech clients, potential clients, and product distributors.

Tim Shriver has his name on the issued patents and the patent applications. I've seen him answer questions and explain the technology and application prototypes to Baxa, CDEX users, and potential CDEX users. My hope is that Tim Shriver will be successful in advancing the technology to a point where it's potential can become real, without diluting the stuffing out of the outstanding CDEX shares.

Larry Marsteller, M.D., seems to remain on-board, and just like Mr. Shriver, Dr. Marsteller has his name on CDEX intellectual property, and just like Mr. Shriver, I've seen him answer questions and explain the technology and application protoypes to Baxa, CDEX users (including other MDs), and potential CDEX users. I was very pleasantly surprised to see Dr. Marsteller demonstrate a solid business perspective as well. Those financial credentials described on the CDEX website profile page bring some comfort as I worry about corporate finances.

http://www.cdex-inc.com/profile.html

Dr. Laurence J. Marsteller, Director of Research and Development, is a practicing M.D. with a background in physics, business management and investment banking. Dr. Marsteller has served as CDEX Director of R&D since 2005, and first joined the company in 2003. He maintains a limited private practice in family medicine, and has held leadership roles with healthcare providers, including the Ascension Health/Carondelet Health Network where he serves on the Medical Executive Committee and is Chair of the Department of Family Practice at Ascension Health/Carondelet St. Joseph’s Hospital. Dr. Marsteller has delivered testimony before the Food and Drug Administration Counterfeit Task Force to help develop programs for the FDA and other agencies to combat the problem of counterfeit pharmaceuticals and biologics. Before pursuing medicine, his interests and educational background led him to positions in investment banking with Morgan Stanley and Shearson Lehman, as well as a research position with the University of Arizona Lunar and Planetary Lab, Steward Observatory. Dr. Marsteller holds an M.D. from the University of Arizona College of Medicine, a M.Sc. in Astronomy from Yale University, and a B.Sc. in Physics from Georgetown University.

= = = = = = =

Dr. Poteet seems to remain on-board. One interesting note - it seemed a change of pace to see Dr. Poteet interviewed and describing the hand-held illicit drug detector / meth gun. I'll leave it at that as there is plenty I've written re: Dr. Poteet.

Above all, I believe as much as ever that the CDEX technology is real, and the CDEX technology is important, and the CDEX technology has value. I believe the University of Michigan, and I believe the names on the CDEX patents and applications represent folks that want CDEX to succeed and want CDEX to provide a return on investment.

http://www.uspto.gov/patft/index.html

United States Patent 7,154,102
Poteet , et al. December 26, 2006

--------------------------------------------------------------------------------
System and methods for detection and identification of chemical substances


Abstract
The invention provides a system and method utilizing, among other things, fluorescence spectroscopy in the ultraviolet portion of the electromagnetic spectrum to determine chemical species and concentrations. The basic measuring system includes optics, a spectrograph, a detector, and an energy source ("head" components), along with a computer and control electronics and power source capable of generating and detecting unique fluorescence signatures for individual and unique mixtures of chemical substances including, for example, prescribed and/or compounded medications, alcohol products, food types, synthetic drugs, narcotics, perfumes, liquids, and the like.


--------------------------------------------------------------------------------
Inventors: Poteet; Wade Martin (Tucson, AZ), Marsteller; Laurence (Tuscon, AZ), Shriver; Timothy D. (Vail, AZ)
Assignee: CDEX, Inc. (Rockville, MD)

= = = = = = =
= = = = = = =

United States Patent 7,106,826
Poteet , et al. September 12, 2006

--------------------------------------------------------------------------------
System and method for adapting a software control in an operating environment


Abstract
A system and method for detecting a substance using x-ray fluorescence is disclosed. The detected substances may be explosives or controlled substances that have a specific chemical fluorescent signature. An energy source transmits an x-ray beam at a target. The target may be in a container or under a surface. The beam interacts with the target to produce fluorescent energy. An x-ray detector is at an angle relative to the energy source and gathers the fluorescent energy. The angle differs according to the physical configuration of the system. A portable embodiment will have a different angle than a stationary embodiment. A cooling mechanism cools the x-ray detector. The fluorescent energy is analyzed and processed by a multichannel analyzer and a computer. The computer determines whether the fluorescent energy from the target matches known fluorescent energies of specific substances. If the substance is detected, appropriate indications are made to prevent damage or acceptance of the substance.


--------------------------------------------------------------------------------
Inventors: Poteet; Wade M. (Tucson, AZ), Cauthen; Harold K. (Sonoita, AZ), Shriver; Timothy D. (Tuscon, AZ)
Assignee: CDEX, Inc. (Rockville, MD)

= = = = = = =

United States Patent Application 20070019189
Kind Code A1
Marsteller; Laurence ; et al. January 25, 2007

--------------------------------------------------------------------------------
Cuvette and cuvette cap


Abstract
The invention provides a cuvette apparatus having two cavities that are in fluid communication with each other. The first cavity is larger than the second cavity an receives a fluid to be studied. The second cavity holds the fluid for analysis and is bounded by at least two thin walled windows that allow superior transmission of UV waves, The invention also provides a cuvette cap that can be affixed to the cuvette and which seals the cuvette, thus preventing potentially dangerous vapors from escaping from the cuvette.


--------------------------------------------------------------------------------
Inventors: Marsteller; Laurence; (Tucson, AZ) ; Cauthen; Harold K.; (Sonoita, AZ) ; Poteet; Wade Martin; (Tucson, AZ) ; Alvarez; Jose Carlos; (Tucson, AZ) ; Poteet; Stuart Clark; (Tucson, AZ)
Correspondence Name and Address: HOGAN & HARTSON LLP;IP GROUP, COLUMBIA SQUARE
555 THIRTEENTH STREET, N.W.
WASHINGTON
DC
20004
US


Assignee Name and Adress: CDEX, Inc.

= = = = = = =

PUB. APP. NO. Title
1 20070019189 Cuvette and cuvette cap
2 20060291620 System and method for adapting a software control in an operating environment
3 20050077476 System and methods for detection and identification of chemical substances
4 20040155202 Methods and apparatus for molecular species detection, inspection and classification using ultraviolet fluorescence
5 20030128804 System and method for adapting a software control in an operating environment

= = = = = = =

http://www.cdex-inc.com/pr/63006.html

CDEX Files Apparatus Patent Application for Portable, Hand-held Methamphetamine and Illicit Drug Detector

= = = = = = =
http://www.baxa.com/Products/RelatedDocs/ASHP%20UM%20Fluorometry%20Poster.pdf

Disclosure
The authors of this presentation have the following to
disclose concerning possible financial or personal
relationships with commercial entities:
Dr. Kaakeh: nothing to disclose
Dr. Stevenson: nothing to disclose
Dr. De Smet: nothing to disclose
Mr. Kirsch: Technical Consultant (CDEX, Inc.)
Dr. Phan: nothing to disclose
Ms. Glenn: nothing to disclose
Dr. Pasko: nothing to disclose
Dr. Mitchell: nothing to disclose


= = = = = = =

http://www.michiganpharmacists.org/fluorometry.pdf

James G. Stevenson, Pharm.D., FASHP
YamanKaakeh, Pharm.D.
Brian De Smet, Pharm.D.
Hanna Phan, Pharm.D.
Denise Glenn, BS Pharm
Deborah Pasko, Pharm.D.
John Mitchell, Pharm.D.
University of Michigan Health System
University of Michigan College of Pharmacy

Pursuit of Improved Process at the University of Michigan
•Troubled by near miss involving heparin and insulin in December 2004
•Jim Jorgenson –University of Utah
−Described use of fluorometry in OR returns
−Planning to assess in chemotherapy preparation
•Contacted manufacturer, CDEX, Inc., to determine potential interest in applying technology to high risk parenteralcompounding in the pharmacy

Advantages of Fluorescence
•Good sensitivity & specificity
•Relatively high speed
•Relatively inexpensive compared to chemical analysis
•Simple to perform
•Refractometrynot capable of distinguishing low concentrations of drugs in standard diluents
•True “end product testing” vs. bar coding

•ValiMed has been demonstrated to be capable of reliably detecting significant errors

•Device has prevented at least three significant errors since implementation

http://www.michiganpharmacists.org/fluorometry.pdf